Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Tardive Dyskinesia Treatment Market: By Drug Class, By Disorder, By Distribution Channel and Region
Tardive Dyskinesia Treatment Market: By Drug Class, By Disorder, By Distribution Channel and Region
Tardive Dyskinesia Treatment Market size was valued at US$ 5.68 billion in 2023 and is poised to grow at a CAGR of 4.2% from 2024-2030. Tardive dyskinesia is a neurological condition in which involuntary movements are involved. The phrases tardive and dyskinesia can be defined as delayed and aberrant movement, respectively. Finger movement, facial grimacing, jaw swinging, repetitive chewing, constant blinking of the eyes, tongue pushing, and other symptoms of tardive dyskinesia.
Tardive dyskinesia is a side effect of neurotic medications. These drugs are also known as anti-psychotics or strong tranquilizers. These medications are mostly used to treat mental illnesses. When you use a drug for months or years, you may develop tardive dyskinesia. Because the drug that can be used to treat tardive dyskinesia has not yet been licensed, and the method of treatment has not yet been validated, treating the disease is a challenging undertaking. The patient's neurological system is affected by the tardive dyskinesia treatment. Because the drug that can be used to treat tardive dyskinesia has not yet been licensed, and the method of treatment has not yet been validated, treating the disease is a challenging undertaking. The patient's neurological system is affected by the tardive dyskinesia treatment.
Study Period
2024-2030Base Year
2023CAGR
4.2%Largest Market
North-AmericaFastest Growing Market
North-America
In the approaching years, the market for tardive dyskinesia treatment will expand dramatically. The increasing number of people suffering from neurological problems is a major element driving the tardive dyskinesia therapy market. The majority of the population in North America suffers from tardive dyskinesia, and individuals are eagerly anticipating treatment, driving the market's growth. The approval process for new treatment modalities by the respective association is a stumbling block to market growth.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 5.68 billion |
|
Market CAGR |
4.2% |
|
By Drug Class |
|
|
By Disorder |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The global tardive dyskinesia treatment market size was valued at US$ 5.68 billion in 2023 and is projected to grow at a CAGR of 4.2% from 2024-2030.
Biogen (U.S) Teva Pharmaceutical Industries Ltd. (Israel) GlaxoSmithKline Plc.(U.K) Johnson & Johnson Services, Inc.(U.S) Pfizer Inc.(U.S) Neurocrine Biosciences, Inc.(U.S)
The tardive dyskinesia treatment market segments are by drug classes, disorder, and distribution channel
| 1.Executive Summary |
| 2.Global Tardive Dyskinesia Treatment Market Introduction |
| 2.1.Global Tardive Dyskinesia Treatment Market - Taxonomy |
| 2.2.Global Tardive Dyskinesia Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Disorder |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Tardive Dyskinesia Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Tardive Dyskinesia Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Tardive Dyskinesia Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Beta-blockers |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Vitamin E Systemic |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. VMAT2 Inhibitors (vesicular monoamine transporter-2 inhibitors) |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Dopaminergic Agents |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Benzodiazepines |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Tardive Dyskinesia Treatment Market By Disorder, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Bradykinesia |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Hyperkinesia |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Tardive Dyskinesia Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Tardive Dyskinesia Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Tardive Dyskinesia Treatment Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Beta-blockers |
| 9.1.2.Vitamin E Systemic |
| 9.1.3.VMAT2 Inhibitors (vesicular monoamine transporter-2 inhibitors) |
| 9.1.4.Dopaminergic Agents |
| 9.1.5.Benzodiazepines |
| 9.2. Disorder Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Bradykinesia |
| 9.2.2.Hyperkinesia |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Retail Pharmacies |
| 9.3.3.Online Pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Tardive Dyskinesia Treatment Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Beta-blockers |
| 10.1.2.Vitamin E Systemic |
| 10.1.3.VMAT2 Inhibitors (vesicular monoamine transporter-2 inhibitors) |
| 10.1.4.Dopaminergic Agents |
| 10.1.5.Benzodiazepines |
| 10.2. Disorder Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Bradykinesia |
| 10.2.2.Hyperkinesia |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Retail Pharmacies |
| 10.3.3.Online Pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Tardive Dyskinesia Treatment Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Beta-blockers |
| 11.1.2.Vitamin E Systemic |
| 11.1.3.VMAT2 Inhibitors (vesicular monoamine transporter-2 inhibitors) |
| 11.1.4.Dopaminergic Agents |
| 11.1.5.Benzodiazepines |
| 11.2. Disorder Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Bradykinesia |
| 11.2.2.Hyperkinesia |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Retail Pharmacies |
| 11.3.3.Online Pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Tardive Dyskinesia Treatment Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Beta-blockers |
| 12.1.2.Vitamin E Systemic |
| 12.1.3.VMAT2 Inhibitors (vesicular monoamine transporter-2 inhibitors) |
| 12.1.4.Dopaminergic Agents |
| 12.1.5.Benzodiazepines |
| 12.2. Disorder Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Bradykinesia |
| 12.2.2.Hyperkinesia |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Retail Pharmacies |
| 12.3.3.Online Pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Tardive Dyskinesia Treatment Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Beta-blockers |
| 13.1.2.Vitamin E Systemic |
| 13.1.3.VMAT2 Inhibitors (vesicular monoamine transporter-2 inhibitors) |
| 13.1.4.Dopaminergic Agents |
| 13.1.5.Benzodiazepines |
| 13.2. Disorder Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Bradykinesia |
| 13.2.2.Hyperkinesia |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Retail Pharmacies |
| 13.3.3.Online Pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Biogen (U.S) |
| 14.2.2.Teva Pharmaceutical Industries Ltd. (Israel) |
| 14.2.3.GlaxoSmithKline Plc.(U.K) |
| 14.2.4.Johnson & Johnson Services, Inc.(U.S) |
| 14.2.5.Pfizer Inc.(U.S) |
| 14.2.6.Neurocrine Biosciences, Inc.(U.S) |
| 14.2.7.Novartis AG (Switzerland) |
| 14.2.8.AstraZeneca (U.K) |
| 14.2.9.Bayer AG (Germany) |
| 14.2.10.Sanofi (France) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.